Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,245 across all filing types
Latest filing 2022-07-06 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
General updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) regarding the issuance of duplicate share certificates to a shareholder. It references Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate management. The content is about share certificate issuance and does not contain financial data, management discussion, voting results, or any report publication. It is an announcement related to share certificates but not a capital change or share issue announcement in the typical sense (like new shares or stock splits). It also does not fit into insider dealings or major shareholding notifications. The best fitting category is Regulatory Filings (RNS) as it is a regulatory compliance announcement that does not fit other specific categories.
2022-07-06 English
Pursuant to Regulation 39(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Registrar and Share Transfer ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) regarding the issuance of duplicate share certificates to a shareholder. It references Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to share certificate management. The content is about share certificate issuance, not about financial results, management changes, or other report types. It is a regulatory announcement related to shareholding documentation but does not fit into categories like Major Shareholding Notification (MRQ) or Share Issue/Capital Change (SHA) since it concerns duplicate certificates, not new shares or ownership changes. Given the nature and content, this fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. The document length is short (2570 characters), and it is a direct announcement, not a report or presentation.
2022-07-06 English
Closure of trading window
Regulatory Filings Classification · 95% confidence The document is extremely short (294 characters) and consists only of addresses and stock exchange listing information without any substantive content, financial data, or report details. It does not contain any report, announcement of voting results, management changes, or financial results. Given the lack of content and the nature of the text, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous filings that do not fit other categories.
2022-06-30 English
This is to inform you that pursuant to Securities Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) informing about the closure of the trading window for insiders and designated persons due to upcoming unaudited financial results for the quarter ended June 30, 2022. It references regulatory compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and states the trading window closure period but does not contain any financial data or results itself. The document is an announcement related to trading restrictions ahead of a financial report, not the report itself. The document length is short (2426 characters), and it is clearly an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance notice.
2022-06-30 English
Annual General Meeting
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Disclosure of Voting Results of the 37th Annual General Meeting of Bliss GVS Pharma Limited held on June 28, 2022 along with Scrutinizer's Report.' It contains detailed voting results for resolutions passed at the AGM, including vote counts, percentages, and information about shareholders present. The document references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 44, which pertains to disclosure of voting results. There is no indication that this is the full AGM report or presentation, but rather the official disclosure of voting outcomes and the scrutinizer's report. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive disclosure of voting results.
2022-06-29 English
In accordance with the Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith the voting results of 37th Annual General Meeting ....
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Disclosure of Voting Results of the 37th Annual General Meeting of Bliss GVS Pharma Limited held on June 28, 2022 along with Scrutinizer's Report.' It contains detailed voting results for resolutions passed at the AGM, including vote counts, percentages, and information about shareholders present. The document references Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of voting results. The content is focused on the official announcement of voting outcomes from the AGM, not the AGM materials themselves or the full annual report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-06-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.